There’s never been a time when science and technology have formed such a powerful union as they do right now. We’re able to identify new targets using AI/ML in an unprecedented way to anticipate treatment prognosis. We’re also able to use more approaches than ever before to discover more efficient ways to serve patients and healthcare professionals.
Discover in this session how GSK is incorporating technology and how it is developing science to get ahead of disease.
We will talk about digital twins, digital therapeutics, AI/ML to help patients, lab efficiency, immersive training, and how the ecosystem is evolving to bring hope to the table. Are you in?
KEYNOTE: GSK: science and technology to provide hope
Eloy Gómez Palomo, VP & Oncology Director - GSK
KEYNOTE: Digital Twins: how are we using advanced technology to accelerate development?
Matt Harrison, VP Digital Sciences Vaccines - GSK
KEYNOTE: Digital Health: Data to power health impact at scale
Lisa Banks, VP Digital Health & Innovation - GSK
KEYNOTE: AI/ML for decision-making in Hematology
Dr. Adrián Mosquera, Hematologist at Santiago de Compostela Hospital
ROUNDTABLE: Partnering to provide cutting-edge technology to the hematology lab
Moderator: Miguel Ferreira, Hematology Franchise Lead - GSK
Dra. Luz Muñoz, Director of Clinical Laboratory, Parc Taulí University Hospital
Miguel Luengo-Oroz, CEO, Spotlab
ROUNDTABLE: OncoGYN, when technology partners with hospitals to deliver what patients need
Moderator: Sara A. Pedraz, Innovation Lead - GSK
Dra. Beatriz Pardo, Director Oncologist, Catalan Institute of Oncology
Dr. Jordi Ponce, Head of Gynecology, Bellvitge University Hospital
e-llas: collaboration to move from cancer to hope
Manuela Doménech, Oncology Franchise Lead - GSK
Sara A. Pedraz, Innovation Lead - GSK
Moderator: Manuela Doménech, Oncology Franchise Lead - GSK
Carlos Pérez, Telefónica
Jennifer Verhelle, Cumlaude Lab
Marisa Cots, AMOH
CLOSURE: Cristina Henríquez de Luna, SVP & GM Spain, Israel, Portugal - GSK
Doors Open: 14:30